Murtaza Shakir, MD
Surgical Oncology · Katy, TXNPI 1063602399
Payments from drug & device makers
Across 53 payments — averaging $23.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$158
- AbbVie$92
- Intuitive Surgical$90
- Tersera Therapeutics LLC$82
- Davol Inc.$74
- TELA Bio, Inc.$64
- plus $685 from 23 others
What the payments were for
- Food & beverage$1,23199%
- Education$131%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(3 entities) | 7 | $158 |
| AbbVie | 1 | $92 |
| Intuitive Surgical | 2 | $90 |
| Tersera Therapeutics LLC | 5 | $82 |
| Davol Inc. | 2 | $74 |
| TELA Bio, Inc. | 3 | $64 |
| Amgen | 3 | $64 |
| Merck | 3 | $50 |
| AstraZeneca | 3 | $49 |
| Octapharma USA, Inc. | 1 | $49 |
| Lilly USA, LLC | 2 | $48 |
| E.r. Squibb & Sons, L.L.C. | 2 | $48 |
| Seagen Inc. | 2 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $42 |
| Hologic Sales And Service, LLC | 1 | $38 |
| Bristol Myers Squibb | 1 | $31 |
| Myovant Sciences Inc. | 1 | $27 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Coherus Oncology, Inc. | 1 | $20 |
| Novartis | 1 | $20 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Ipsen Biopharmaceuticals, Inc | 1 | $16 |
| Cumberland Pharmaceuticals, Inc. | 1 | $15 |
| Biom'up France SAS | 1 | $15 |
| Medela LLC | 1 | $14 |
| Boston Scientific | 1 | $13 |
| GSK | 1 | $13 |
| AMAG Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$1,244 in reported general payments places this provider in the 35th percentile of 191 surgical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tramadol Hcl | 58 | $177 |
| Tamsulosin Hcl | 16 | $63 |
Paid to pharmacies, not to this prescriber.
Other surgical oncology in Katy
- Jennifer WargoHouston$6M
- Ernest CampHouston$3.6M
- Hop Tran CaoHouston$928K
- Elizabeth GrubbsHouston$750K
- Alastair ThompsonHouston$568K
- Merrick RossHouston$283K
- Adam YoppDallas$281K
- Allison DipasqualeDallas$272K
- Patricio PolancoDallas$219K
- Steven CurleyTyler$208K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.